# A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

> **NCT05482087** · PHASE2 · UNKNOWN · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 190 (estimated)

## Conditions studied

- ALK-positive NSCLC

## Interventions

- **DRUG:** XZP-3621

## Key facts

- **NCT ID:** NCT05482087
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2025-05-07
- **Final completion:** 2025-07-01
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2022-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05482087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05482087, "A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05482087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*